Martha E. Manning - Aug 7, 2023 Form 4 Insider Report for MARINUS PHARMACEUTICALS, INC. (MRNS)

Role
SVP, GEN. COUNSEL & CORP. SEC.
Signature
/s/ Debra A. Mohollen, Attorney-in-Fact
Stock symbol
MRNS
Transactions as of
Aug 7, 2023
Transactions value $
-$20,790
Form type
4
Date filed
8/8/2023, 09:05 PM
Previous filing
Jan 30, 2023
Next filing
Jan 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNS Common Stock Sale -$20.7K -2.17K -6.16% $9.54 33K Aug 7, 2023 Direct F1, F2
transaction MRNS Common Stock Sale -$98 -11 -0.03% $8.93 33K Aug 8, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units.
F2 The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.34 to $9.84, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $8.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.